MHR Fund Management’s Iovance Biotherapeutics IOVA Stock Holding History

MHR Fund Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$121M	Hold	28,967,103	–	–	6.28%	4
2026 Q1	$102M	Hold	28,967,103	–	–	7.43%	4
2025 Q4	$79.1M	Hold	28,967,103	–	–	6.81%	4
2025 Q3	$62.9M	Hold	28,967,103	–	–	6.16%	4
2025 Q2	$49.8M	Buy	28,967,103 +4,550,000	+19%	+$11.3M	5.53%	5
2025 Q1	$81.3M	Hold	24,417,103	–	–	9.77%	4
2024 Q4	$181M	Buy	24,417,103 +420,000	+2%	+$3.89M	19.98%	2
2024 Q3	$225M	Hold	23,997,103	–	–	24.57%	2
2024 Q2	$192M	Hold	23,997,103	–	–	23.45%	1
2024 Q1	$356M	Buy	23,997,103 +4,000,000	+20%	+$46.6M	34.36%	1
2023 Q4	$163M	Hold	19,997,103	–	–	17.76%	3
2023 Q3	$91M	Buy	19,997,103 +8,000,000	+67%	+$52.2M	11.15%	5
2023 Q2	$84.5M	Hold	11,997,103	–	–	11.88%	5
2023 Q1	$73.3M	Hold	11,997,103	–	–	9.86%	5
2022 Q4	$76.7M	Buy	+11,997,103	New	+$93.7M	13.08%	5

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MHR Fund Management's IOVA Position: Q2 2026 in Review

MHR Fund Management held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 28,967,103 shares worth $121M. The position accounts for 6.28% of the portfolio, ranked #4.

MHR Fund Management first reported a position in IOVA in Q4 2022 and has held it in 15 quarters since. The position peaked at $356M in Q1 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

MHR Fund Management held 28,967,103 shares of Iovance Biotherapeutics worth $121M as of Q2 2026.
MHR Fund Management left its Iovance Biotherapeutics share count unchanged in Q2 2026.
Iovance Biotherapeutics made up 6.28% of MHR Fund Management's portfolio in Q2 2026, its #4 holding.
MHR Fund Management first reported a position in Iovance Biotherapeutics in Q4 2022 and has held it in 15 quarters since.
MHR Fund Management's Iovance Biotherapeutics position peaked at $356M in Q1 2024.
293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on MHR Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.